Eosinophillic glanuromatosis with polyangitis (EGPA) usually occurs in patients with a recent history (usually less than 10 years) of uncontrolled bronchial asthma. Here we describe a case of EGPA that occurred in a 68-year-old female who had well-controlled bronchial asthma for 17 years. A leukotriene receptor antagonist that had been prescribed one week before onset might have triggered the disease. Our case shows that there is a wide spectrum of clinical characteristics of EGPA, making diagnosis difficult in a primary care setting.
Introduction
Eosinophillic glanuromatosis with polyangitis (EGPA), previously called Churg-Strauss syndrome, causes necrotizing vasculitis in small and medium-sized blood vessels. 1 Among cases of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, EGPA is extremely rare (approximately one case per 1 million population per year) and its clinical characteristics in the Japanese population have not been well established.
Clues for the diagnosis of EGPA are A) preceding bronchial asthma, B) eosinophilia and C) the presence of vasculitis. In general, about 80% of patients with EGPA have a recent history of moderate to severe asthma. 2 However, Shimoi et al. reported that patients with a long history of asthma or even without such a past medical history can be diagnosed as having EGPA. 3 This is a report of a case of EGPA showing an atypical manifestation and the clinical course.
Case Presentation
A 68-year-old woman who had suffered from bronchial asthma for 17 years was admitted to our hospital following two weeks of prolonged fatigue, paralysis and dysesthesia of the extremities. Before admission, she had consulted her physician and was prescribed with montelukast. The paralysis was accompanied by pain and numbness which progressively spread from her right leg and further to the upper extremities. Her family history included Sjögren's syndrome in her sister. She had no habit of alcohol or tobacco use. The results of the laboratory tests were as follows: white blood cell count, 17,870/µL; eosinophilia (53.5%, 9,560/µL); erythrocyte sedimentation ratio, 59 mm/ 1 hour; rheumatoid factor, 49.5 IU/mL; myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA), more than 134 U/mL; C-reactive protein, 1.25 mg/dL; proteinuria and hematuria ( Table 1) . The results of electrocardiography and cardiac ultrasonography were normal. Pulmonary involvement was not detected by computed tomography, and the results of a respiratory function test were within the normal range. Though proteinuria and occult blood in urinalysis were seen on admission, renal biopsy was not seen as necessary.
A nerve conduction study showed that motor and sensory compound muscle action potentials of median, ulnar, tibial and peroneal nerves were bilaterally declined. Conduction of her left ulnar and median nerves was totally blocked between the left wrist and elbow, indicating poly-mononeuropathy. Hematoxylin and eosin staining of her left sural nerve showed an Subsequently, corticosteroid therapy was gradually tapered and a second course of cyclophosphamide hydrate was administered on day 31. The eosinophilia, abnormality in urinalysis and elevation of MPO-ANCA were improved by the treatment (Figure 1) .
Her neurological symptoms, except for muscle strength of her left ankle dorsal flexion and the numbness of her left lower leg, disappeared within one month.
Discussion
The clinical course of our patient had some interesting points we should learn from. The first issue is the time interval from the initial episode of bronchial asthma and the occurrence of EGPA. As stated above, patients with EGPA characteristically have complications with moderate or severe asthma. 4 Typically, asthma precedes the vasculitic phase by about 8 to 10 years. 5, 6 In the Japanese population, the average duration of precedent asthma was reported to be 6.1 years. 3 Our case was unique in that EGPA occurred 17 years after the initial onset of asthma. Physicians should be aware that EGPA cannot be ruled out because of a long history of asthma.
The second issue is the relevance of severity of asthma and the occurrence of EGPA. In general, EGPA occurs in patients with a moderate or severe state of bronchial asthma. 4 Respiratory symptoms in our patient were well controlled with an inhaled corticosteroid and there had been no asthma attacks for at least 5 years. We may need to recall EGPA as a possible differential diagnosis in patients with any state of bronchial asthma.
Since a first report on a relationship between administration of an LTRA and onset of EGPA, 7 it has been a matter of debate. 8 DuMouchel et al reported that there was a strong relevance between LTRA use and AGA. 9 The possible pathophysiological mechanisms are assumed to be (i) allergic reaction to LTRA, 10 (ii) leukotriene imbalance, 11 (iii) altered cytokine pattern by LTRA, 12 (iv) unmasking phenomenon due to alternatively tapered corticosteroid. 13 Our patient was prescribed montelukast for one week which could be associated with the onset of EGPA. It was possible that In the primary care setting, the recording of medical histories with great care is an essential tool for making a complete diagnosis. Our case was unique in terms of a very long interval (17 years) between the onsets of asthma and EGPA, in which EGPA occurred when asthma was well controlled. Due to its rarity, the clinical characteristics of patients with EGPA, especially in Japanese patients, have not been completely elucidated and a further accumulation of such cases is needed for a better understanding of the disease.
